Table 1.

Patient characteristics.

Patient characteristics	Results	N = 19,705	%	Missing	%
Sex assigned at birth	Female	7626	38.7	0	0
	Male	12,079	61.3	0	0
Diagnosis	CLL	18,386	93.3	0	0
	MBL	791	4	0	0
	SLL	528	2.7	0	0
Survival status	Alive	13,524	68.6	0	0
	Dead	5984	31.4
Comorbidities at diagnosis	No	4271	30	5489	27.9
	Yes	9945	70
Treatment status	Treated	10,146	52.6	433	2.2
	Untreated	9126	47.4
Type of treatment	CIT or/and chemotherapy	7128	71.3	147	1.4
	CIT or/and chemotherapy and novel agents	1940	19.4
	Only novel agents	600	6
	Other	331	3.3
IGHV gene status	Mutatedb	4256	50.5	11,269	57.2
	Unmutatedc	4180	49.5
del(13q)	Negative	4851	52.7	10,507	53.3
	Positive	4347	47.3
del(11q)	Negative	8334	86.5	10,068	51.1
	Positive	1303	13.5
Trisomy 12	Negative	7531	82.5	10,578	53.7
	Positive	1596	17.5
del(17p)	Negative	8992	90.4	9755	49.5
	Positive	958	9.6
TP53 mutation status	Mutated	604	13.5	15,244	77.4
	Unmutated	3857	86.5
Karyotypea	Normal	2107	52.2	15,668	79.5
	Abnormal	1930	47.8
Other malignant neoplasms	No	15,571	79	0	0
	Yes	4134	21
Time of other malignant neoplasms	Before CLL diagnosis	872	21.1	0	0
	After CLL diagnosis	2940	71.1
	Before and after CLL	322	7.8
Multiple other malignant neoplasms	Two or more non-hematological	464	2.4	0	0
	Both non-hematological and hematological	212	1
	Two hematological	16	0.08
Transformation	No	19,072	96.8	0	0
	Yes	633	3.2
Type of transformation	DLBCL	559	88.3	0	0
	HL	35	5.5
	PLL	18	2.8
	Burkitt lymphoma	3	0.5
	Other	18	2.8

CIT, chemoimmunotherapy; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; MBL, monoclonal B lymphocytosis; IGHV, immunoglobulin heavy variable; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin's lymphoma; PLL, B cell prolymphocytic leukemia.

^aKaryotype specific abnormalities: Complex Karyotype (≥3 abnormalities): 384 (9.5%), Trisomies 12 & 19: 50 (1.2%), 6q deletions: 62 (1.5%), Translocations of 14q: 54 (1.3%), Translocation (14; 19): 17 (0.4%).

^bMutated: <98% germline identity.

^cUnmutated: ≥98% germline identity.